SciBrunch Therapeutics

SciBrunch Therapeutics is a Shanghai-based biotechnology company specializing in the development of next-generation small molecule oncology treatments. Founded in 2024 by industry veterans from Merck, Amgen, and WuXi AppTec, the company focuses on iterative innovation of clinically validated targets to create best-in-class therapies. Its lead program, SPR1020, is a highly brain-penetrant PARP1 inhibitor currently in Phase 1 clinical development for solid tumors, including breast and ovarian cancers. Additionally, the company is advancing a preclinical pipeline featuring a molecular glue-type RAS inhibitor aimed at difficult-to-treat cancers such as pancreatic and non-small cell lung cancer. SciBrunch has raised approximately $65 million in total capital as of early 2026 to accelerate its clinical and preclinical assets.